V 3X
Alternative Names: Oral therapeutic vaccine V3-X; V3-XLatest Information Update: 30 Nov 2020
At a glance
- Originator Immunitor
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Cholangiocarcinoma
Most Recent Events
- 30 Nov 2020 V3 X is still in phase I/II trials for Cholangiocarcinoma in Mongolia (PO) (Immunitor pipeline, November 2020)
- 01 Feb 2017 Phase-I/II clinical trials in Cholangiocarcinoma in Mongolia (PO) (NCT03042182)